Skip to main content
. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789

Table 3. Adverse events.

AEs N = 90
AEs occurring during the study in ≥5% patients, n (%)
Headache 6 (7)
Nasopharyngitis 6 (7)
Nausea 5 (6)
Weight decrease 5 (6)
Rash 5 (6)
Study drug-related adverse events occurring in >1 patient
Nausea 3 (3)
Creatinine renal clearance decreased 2 (2)
Serious adverse events
HCC (not related to study drug) 1 (1)

AE, adverse event; HCC, hepatocellular carcinoma.